Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.
Impact Biomedical Inc. Announcement Stock Activity / Pricing
Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.
Impact Biomedical Inc. Announces Acquisition of Celios®
Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality”
Impact BioMedical Inc. to Present at The Microcap Conference
Impact Biomedical Inc. today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors.
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your support, and some additional insights into why we are excited for the future and continued success of Impact BioMedical Inc!
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) — Impact Biomedical Inc. (IBIO), in which DSS Inc.
(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its
innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has
issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this
platform.